Kidney Cancer

November, 2022 Telix Pharmaceuticals sees positive results in kidney cancer imaging study

November, 2022 Integrative Care May Be Beneficial During Treatment for Kidney Cancer

November, 2022 The Latest Breakthroughs That Could Improve Kidney Cancer Treatment

November, 2022 Probiotic May Rev Up Response to Immunotherapy in Advanced Kidney Cancer

November, 2022 Stereotactic Ablation Radiation for Systemic Therapy-Naive Oligometastatic Kidney Cancer

November, 2022 We wanted to try something new' | Texas man diagnosed with Stage 4 kidney cancer undergoes 'groundbreaking’ treatment

2022 Immunotherapy combination shrinks tumors in surgery-ineligible renal cell carcinoma

November, 2022 Tivozanib Maintains Long-Term PFS Benefit Over Sorafenib in Relapsed/Refractory RCC

November, 2022 NICE Recommends Neoadjuvant Pembrolizumab/Chemotherapy, Followed by Adjuvant Pembrolizumab for TNBC

Overview of Kidney Cancer

The kidneys are a pair of 4 or 5 inch long bean-shaped organs located in the back of the abdomen, on either side of the spine. The function of the kidneys is to filter the blood, remove wastes, control fluid balance, regulate electrolytes and make urine.

Kidney Cancer, also called Renal Cancer, is a disease where kidney cells become malignant, grow uncontrollably and form a tumor. Most kidney cancers start in the lining of very small tubules in the kidney. These renal cell carcinomas account for 90% of kidney cancer. Kidney cancer occurs most often in people age 55 or older, and is slightly more common in men.

Renal cell carcinoma usually grows as a single mass within a kidney. In rare cases, there are two or more tumors in one kidney, or tumors in both kidneys. Renal cell carcinomas are usually fast growing and can spread to the lungs and surrounding organs.

Types and Treatments of Kidney Cancer

There are three main types of adult kidney cancer, including renal cell carcinoma, transitional cell carcinoma and renal sarcoma, which may require a combination of surgery, radiation therapy, chemotherapy, immunotherapy/biologic therapy, and/or targeted therapy.

Renal cell carcinoma: renal cell carcinoma (RCC) accounts for about 90% of kidney cancers, and arises from the lining of the small tubules of the kidney.

Subtypes and treatments of Renal Cell Carcinoma include:

  • Clear cell RCC: the most common form of kidney cancer (65-75% of cases). Clear cell RCC is associated with Hippel-Lindau gene mutation in hereditary kidney cancer. Clear cell RCC can be slow-growing or fast growing. Treatments usually include surgery for early stage and immunotherapies for later stages.
  • Papillary kidney cancer: is the second most common type of kidney cancer (10-15% of cases). Papillary kidney cancer is divided into Type I and Type II subtypes based on cell appearance, and is associated with Heriditary Papillary RCC and Hereditary Leiomyomatosis syndrome. Surgical removal is performed in early stages, chemotherapy and immunotherapy is used for cancer that has spread.
  • Collecting duct carcinoma: is a rare form of RCC and is usually treated with chemotherapy.
  • Medullary RCC: is a rare and aggressive type of kidney cancer that is associated with the sickle cell trait. Chemotherapy is usually the treatment for medullary RCC.
  • Chromophobe RCC: is a rare form (5%) of kidney cancer which is sometimes associated with a specific gene mutation called Birt Hogg Dube syndrome.
  • Unclassified renal cell carcinomas: are RCCs that contains more that one type of cell type and are usually characterized as aggressive cancers.

Transitional cell carcinoma: account for 5-10% of kidney cancers, and originates in the renal pelvis. If the cancer has not spread, surgical removal of the kidney and ureter is usually the treatment plan. If the tumor has metastasized, treatment options are similar to metastatic bladder cancer, which includes chemotherapy.

Renal carcinoma: is a very rare form (1%) of kidney cancer, which is treated with chemotherapy, surgery and radiation.

Recent News for Kidney Cancer

Targeted Therapy Proves Its Worth in Metastatic Kidney Cancer Patients
July 11, 2019

73% of Kidney Cancer Patients Respond to Inlyta-Keytruda Combo, Trial Shows
February, 2018

GU Cancer Symposium 2018
Tecentriq-Avastin Combo In Advanced Kidney Cancer
February, 2018

Sunitinib or Everolimus First-Line for Kidney Cancer
Journal of Clinical Oncology
July 24, 2014

Enzyme may halt tumor growth in kidney cancer
Medical News Today
July 22, 2014

Expanding the playing Field: Immune-Based Therapy Shows Potential
NCI Cancer Bulletin
June, 2012

CLEAR Study Readout Shows Survival Enhancement With Lenvatinib Plus Pembrolizumab Versus Sunitinib in Frontline RCC
Cancer Network
February, 2021

FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC

Support Groups for Kidney Cancer

Kidney Cancer Association Support Groups

Daily Strength Kidney cancer Support Group

Cancer Care Kidney cancer Support Group

Association of Cancer Online Resources

National Kidney Foundation Support Groups

Imerman Angels (to connect directly with another survivor or caregiver through an organization that creates personal, one-on-one connections among patients, survivors, and caregivers)

Fighting Chance (free counseling service for cancer patients and caregivers).